NASDAQ:OBLN - Obalon Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.57
▼ -0.03 (-1.15%)
1 month | 3 months | 12 months
Get New Obalon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBLN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Obalon Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.57.
Buy
The current consensus among 1 polled investment analysts is to buy stock in Obalon Therapeutics. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/18/2021Alliance Global PartnersUpgradeNeutral ➝ BuyLow
i
3/27/2020Alliance Global PartnersDowngradeBuy ➝ NeutralMedium
i
7/24/2019Northland SecuritiesReiterated RatingHoldMedium
i
7/11/2019Northland SecuritiesReiterated RatingHold$10.00Low
i
4/11/2019Northland SecuritiesReiterated RatingHold$10.00Low
i
4/8/2019Canaccord GenuityDowngradeBuy ➝ Hold$30.00 ➝ $15.00High
i
2/26/2019Roth CapitalReiterated RatingBuy ➝ Neutral$60.00 ➝ $27.50High
i
Rating by S. Henry at Roth Capital
2/25/2019Stifel NicolausUpgradeHold ➝ Buy$25.00 ➝ $30.00High
i
2/5/2019Roth CapitalReiterated RatingBuyMedium
i
Rating by S. Henry at Roth Capital
1/3/2019Northland SecuritiesReiterated RatingHold$20.00Low
i
9/12/2018Northland SecuritiesReiterated RatingHold$25.00Medium
i
9/12/2018BTIG ResearchReiterated RatingBuy$35.00Low
i
9/11/2018Stifel NicolausBoost Price TargetHold ➝ Hold$25.00 ➝ $35.00Low
i
9/6/2018Roth CapitalInitiated CoverageBuy$60.00High
i
Rating by D. Solomon at Roth Capital
8/5/2018BTIG ResearchReiterated RatingBuyLow
i
8/3/2018Stifel NicolausLower Price TargetHold ➝ Hold$30.00 ➝ $20.00High
i
8/2/2018Northland SecuritiesUpgradeUnderperform ➝ Market PerformHigh
i
5/11/2018Stifel NicolausDowngradeBuy ➝ HoldLow
i
5/11/2018Northland SecuritiesDowngradeMarket Perform ➝ UnderperformHigh
i
3/6/2018Stifel NicolausReiterated RatingBuyHigh
i
3/6/2018BTIG ResearchLower Price TargetBuy$70.00High
i
3/6/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$110.00 ➝ $100.00High
i
2/21/2018Northland SecuritiesReiterated RatingHold$40.00Low
i
1/25/2018Northland SecuritiesUpgradeUnderperform ➝ Market PerformMedium
i
1/23/2018Northland SecuritiesReiterated RatingSell$40.00Medium
i
1/22/2018Canaccord GenuityReiterated RatingPositive ➝ Buy$150.00 ➝ $110.00Low
i
11/16/2017BTIG ResearchReiterated RatingBuy$150.00N/A
i
11/10/2017UBS GroupLower Price TargetBuy$200.00 ➝ $160.00N/A
i
11/6/2017BTIG ResearchLower Price TargetBuy ➝ Buy$200.00 ➝ $150.00N/A
i
11/3/2017Northland SecuritiesReiterated RatingSell$40.00N/A
i
Rating by Suraj Kalia at Northland Securities
8/9/2017UBS GroupReiterated RatingBuy$220.00 ➝ $200.00Low
i
8/3/2017UBS GroupReiterated RatingBuy$220.00 ➝ $200.00Medium
i
8/2/2017Northland SecuritiesReiterated RatingSell$60.00Medium
i
Rating by Suraj Kalia at Northland Securities
6/21/2017Northland SecuritiesInitiated CoverageUnder Perform$60.00High
i
5/18/2017Canaccord GenuityReiterated RatingBuyLow
i
Rating by Kyle Rose at Canaccord Genuity
4/17/2017Canaccord GenuityReiterated RatingBuyMedium
i
Rating by Kyle Rose at Canaccord Genuity
3/19/2017BTIG ResearchReiterated RatingBuy$200.00Medium
i
2/9/2017Canaccord GenuitySet Price TargetBuy$170.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
1/23/2017Canaccord GenuityReiterated RatingBuy$170.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
11/11/2016Canaccord GenuitySet Price TargetBuy$170.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
10/31/2016Stifel NicolausInitiated CoverageBuy$180.00N/A
i
10/31/2016Canaccord GenuityInitiated CoverageBuy$280.00N/A
i
10/31/2016BTIG ResearchInitiated CoverageBuy$200.00N/A
i
10/31/2016UBS GroupInitiated CoverageBuy$210.00N/A
i
(Data available from 4/14/2016 forward)
Obalon Therapeutics logo
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated. The company was founded on January 2, 2008 and is headquartered in Carlsbad, CA.
Read More

Today's Range

Now: $2.57
$2.51
$2.62

50 Day Range

MA: $3.28
$2.65
$4.35

52 Week Range

Now: $2.57
$0.66
$10.77

Volume

3,016 shs

Average Volume

8,841,961 shs

Market Capitalization

$25.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Obalon Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Obalon Therapeutics in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for OBLN.

What is the current price target for Obalon Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Obalon Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Obalon Therapeutics in the next year.
View the latest price targets for OBLN.

What is the current consensus analyst rating for Obalon Therapeutics?

Obalon Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OBLN will outperform the market and that investors should add to their positions of Obalon Therapeutics.
View the latest ratings for OBLN.

What other companies compete with Obalon Therapeutics?

How do I contact Obalon Therapeutics' investor relations team?

Obalon Therapeutics' physical mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company's listed phone number is (844) 362-2566 and its investor relations email address is [email protected] The official website for Obalon Therapeutics is www.obalon.com.